PIQUR Announces First Human Topical Application of Bimiralisib

A Topical Dual-PI3K/mTOR inhibitor, in healthy volunteers followed by patients with the Rare Disease “Cutaneous T-Cell Lymphoma” in collaboration with the CHDR, LUMC, and SCARLETRED.

Company Started Treatment of Healthy Volunteers with Topical Bimiralisib in Phase 1/2a First-on-Human / Proof of Concept

PIQUR Therapeutics AG (PIQUR), a clinical stage drug development company, today announced that following approval by an Independent Ethics Committee in the Netherlands, the first healthy subjects have been treated with bimiralisib, an investigational drug designed to inhibit the PI3K/mTOR pathway for the treatment of early stage Cutaneous T-Cell Lymphoma (CTCL). The study is run at the Center for Human Drug Research (CHDR) in collaboration with the Cutaneous Lymphoma Expert Centre of the Leiden University Medical Center in the Netherlands. The objective of this single center, multiple-stage, multiple-cohort, randomized, placebo-controlled, double-blind clinical study, is to characterize the safety, tolerability, pharmacokinetics, and efficacy of bimiralisib in healthy volunteers and patients with early stage CTCL..

PIQUR expects to complete the treatment of the healthy volunteer cohort of this combined first-on-human / proof-of-concept study by fall 2019. The local tolerability of bimiralisib will be evaluated using multiple assessments, including daily evaluations of the treated lesions with the Scarletred® Vision App by SCARLETRED. 


The Scarletred® Vision App is a dermatological software platform for objective quantification and remote assessment of skin changes available from the App store. It allows to take standardized skin images which can be either stored locally or securely transferred to the Scarletred® online platform for remote monitoring and optional analysis. 

About PIQUR 

Founded in 2011 as a spin-off of the University of Basel, Switzerland, PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancer and genetic diseases. PIQUR’s lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR is a privately owned company that is backed by private investors and Versant Venture, a leading venture capital firm that specializes in investments in innovative biopharmaceuticals. 

Contact Melanie Rolli, CEO